Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Jan 2, 2020 at 10:25 AM EST

The Top Biopharma Events to Watch in 2020

Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch…

Chris Lange | Jan 2, 2020 at 9:55 AM EST

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe

Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization…

$Why This Refractory Angina Treatment Could Be a Big Hit$

Chris Lange | Dec 31, 2019 at 10:10 AM EST

Why This Refractory Angina Treatment Could Be a Big Hit

Neovasc shares nearly doubled on Tuesday after the firm announced the submission of an application to the FDA for its…

Chris Lange | Dec 30, 2019 at 1:10 PM EST

Is It Over for This Huntington’s Disease Clinical Trial?

Wave Life Sciences shares dropped sharply to start out the week after the company announced topline data from its ongoing…

Chris Lange | Dec 30, 2019 at 12:30 PM EST

Why One Analyst Sees Sarepta’s Roche Deal Taking Off

Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about…

Chris Lange | Dec 30, 2019 at 10:20 AM EST

Why This aPAP Treatment Is a Big Hit

Savara shares more than doubled on Monday after the firm announced that the FDA has granted Breakthrough Therapy designation for…

Chris Lange | Dec 30, 2019 at 9:50 AM EST

AstraZeneca’s FDA Nod Could Be Big

AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.

Chris Lange | Dec 27, 2019 at 1:00 PM EST

Why This Uriniary Tract Infection Trial Could Be Huge

Iterum Therapeutics shares more than doubled on Friday after the firm announced that it had completed the enrollment of its…

Chris Lange | Dec 27, 2019 at 8:50 AM EST

Why This Osteoarthritis Treatment Is Making Waves

Flexion Therapeutics shares popped on Friday after the company announced that the FDA has approved a supplemental New Drug Application…

Chris Lange | Dec 26, 2019 at 3:19 PM EST

The Top Healthy Living ETFs of 2019

Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking greatly increase one’s odds of…

Chris Lange | Dec 26, 2019 at 12:05 PM EST

Could This Breast Cancer Study Be the Next Big Thing?

Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License…

Chris Lange | Dec 26, 2019 at 10:00 AM EST

Why This Cancer Study Is Crushing Spectrum Pharma

Spectrum Pharma shares were halved on Thursday after the firm provided an update on its midstage cancer study some updates…

Paul Ausick | Dec 26, 2019 at 9:46 AM EST

A Third of Adolescents Make Risky Lifestyle Choices

A new analysis of data collected from more than 300,000 adolescents worldwide show that more than a third engage in…

Chris Lange | Dec 26, 2019 at 8:55 AM EST

Big Pharma Short Sellers Get Selective

The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Dec 26, 2019 at 8:40 AM EST

Major Biotechs See Rising Short Interest

The December 13 short interest data has been compared with the previous report, and short interest in most of these…

1 … 73 74 75 76 77 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

The Top Biopharma Events to Watch in 2020

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe

Why This Refractory Angina Treatment Could Be a Big Hit

Is It Over for This Huntington’s Disease Clinical Trial?

Why One Analyst Sees Sarepta’s Roche Deal Taking Off

Why This aPAP Treatment Is a Big Hit

AstraZeneca’s FDA Nod Could Be Big

Why This Uriniary Tract Infection Trial Could Be Huge

Why This Osteoarthritis Treatment Is Making Waves

The Top Healthy Living ETFs of 2019

Could This Breast Cancer Study Be the Next Big Thing?

Why This Cancer Study Is Crushing Spectrum Pharma

A Third of Adolescents Make Risky Lifestyle Choices

Big Pharma Short Sellers Get Selective

Major Biotechs See Rising Short Interest

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Medicare Advantage’s $0 Premium Comes With a $9,250 Catch

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old’s Social Security, But It Can Raise Medicare Two Years Later

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

Medicare Advantage's $0 Premium Comes With a $9,250 Catch

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old's Social Security, But It Can Raise Medicare Two Years Later

Tomorrow’s SpaceX IPO Is Going to Be Insane. Retail Investors Are Trying to Buy the Whole Thing

Forget AI Software: Why the Smart Money is Betting Billions on Autonomous Weapons

Health and Healthcare Articles

All Health and Healthcare Articles

The Top Biopharma Events to Watch in 2020

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe

Why This Refractory Angina Treatment Could Be a Big Hit

Is It Over for This Huntington’s Disease Clinical Trial?

Why One Analyst Sees Sarepta’s Roche Deal Taking Off

Why This aPAP Treatment Is a Big Hit

AstraZeneca’s FDA Nod Could Be Big

Why This Uriniary Tract Infection Trial Could Be Huge

Why This Osteoarthritis Treatment Is Making Waves

The Top Healthy Living ETFs of 2019

Could This Breast Cancer Study Be the Next Big Thing?

Why This Cancer Study Is Crushing Spectrum Pharma

A Third of Adolescents Make Risky Lifestyle Choices

Big Pharma Short Sellers Get Selective

Major Biotechs See Rising Short Interest

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Medicare Advantage’s $0 Premium Comes With a $9,250 Catch

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old’s Social Security, But It Can Raise Medicare Two Years Later

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

Featured Reads

Medicare Advantage's $0 Premium Comes With a $9,250 Catch

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old's Social Security, But It Can Raise Medicare Two Years Later